Status:

WITHDRAWN

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

Lead Sponsor:

Anelixis Therapeutics, LLC

Conditions:

Type 1 Diabetes Mellitus

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Detailed Description

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant. This study will also provide va...

Eligibility Criteria

Inclusion

  • Men and women 18-65 years of age
  • A diagnosis of T1D ≥5 years with onset of disease at \<40 years of age
  • Involvement in intensive diabetes management as directed by an endocrinologist or diabetologist with at least 3 clinical evaluations within the 12 months prior to Screening; using an insulin pump or multiple daily injection (MDI) insulin therapy; and, unable to achieve acceptable metabolic control because of the occurrence of severe hypoglycemia
  • At least 2 unexplained SHEs not secondary to a missed meal or dosing error, etc., in the 12 months prior to Screening
  • Glycosylated hemoglobin (HbA1c) level greater than 7% (53 mmol/mol) and less than 9.5% (80 mmol/mol) inclusive
  • Absence of stimulated C peptide (\< 0.3 ng/mL) in response to a mixed meal tolerance test (MMTT) measured at 60 and 90 minutes after the start of consumption
  • Reduced awareness of hypoglycemia as defined by a Clarke Score \[Clarke 1995\] of 4 or more at the time of Screening, during the Screening period and within the last 6 months prior to the transplant

Exclusion

  • Any previous transplant
  • HbA1c level less than 7% (53 mmol/mol)

Key Trial Info

Start Date :

February 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2026

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04711226

Start Date

February 19 2021

End Date

June 1 2026

Last Update

August 10 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Alberta

Edmonton, Alberta, Canada, T6G 2E1